ANU researchers have created a Trojan horse method using cholesterol to deliver drugs that more effectively kill parasites, offering potential treatments for diseases and protecting livestock.
Over a quarter of Australians aged 50 and above use cholesterol-lowering drugs to prevent heart disease and strokes. However, cholesterol is also essential for survival. Scientists at The Australian National University (ANU) now believe that cholesterol’s fundamental role as a building block of life may be key to treating deadly parasitic diseases, including malaria.
The researchers have developed a trojan horse method that tricks malaria parasites into ingesting a fatal dose of drugs by exploiting the parasite’s need for cholesterol to survive. By attaching cholesterol to drugs, the scientists can “smuggle” the drugs into the parasite where they can exert their killing effect.
The new trojan horse method could lead to more effective and longer-lasting treatments for malaria. According to the scientists, the findings also have implications for the agricultural industry, as parasites can infect and kill livestock, leading to billion-dollar losses for farmers.
Effectiveness and Applications of the New Method
Lead researcher Professor Alex Maier from ANU said the trojan horse method of smuggling drugs into the parasites is three to 25 times more effective at eliminating the parasites compared to drugs that aren’t attached to cholesterol.
“Due to its bad reputation, people often forget that cholesterol is a basic building block of life and humans and animals need it to function and survive. Parasites are particularly desperate for cholesterol, since they have lost the ability to make their own,” Professor Maier said.
“Since parasites can’t produce cholesterol of their own, they steal it from their hosts and stockpile it.”
Addressing Malaria Resistance Challenges
After a mosquito injects the malaria parasites into humans, the parasites eventually enter red blood cells where they hide from the immune system. Although malaria can be cured with drugs, malaria parasites are smart. They are continually finding new ways to adapt and build resistance to current therapies, keeping scientists on their toes.
But the ANU scientists say their new technique, which disguises the drugs under the veil of the cholesterol, addresses this long-standing issue.
“Existing drugs used to treat malaria are taken up passively by the parasite, meaning they’re not as effective as they could be,” Professor Maier said.
“By attaching the drugs to cholesterol, the parasite actively latches onto and eats the cholesterol. This allows us to smuggle drugs into optimal killing zones inside the parasite where the drugs can inflict the most damage.
“Using this approach, we can also repurpose existing drugs that have lost their bite and make them effective again. Essentially, we’re giving new life to existing drugs that have since become redundant.
“This research also paves the way for the development of new, more efficient drugs that are also cheaper to manufacture.”
Broadening the Impact and Future Applications
According to the ANU scientists, this new drug delivery system of coupling drugs with cholesterol could also be used to treat other diseases including giardia, an intestinal disease responsible for causing diarrhea.
It could also help treat leishmaniasis, a skin, mouth, nose, and throat disease that disproportionally impacts some of the world’s poorest people. If not treated, leishmaniasis can be fatal.
Professor Maier said the research could also unlock new and more effective therapies to treat parasitic diseases in companion animals and livestock, which would prevent billions of dollars in damages and provide a major boost to the agricultural industry, including in Australia.
Reference: “Harnessing cholesterol uptake of malaria parasites for therapeutic applications” by Merryn Fraser, Blake Curtis, Patrick Phillips, Patrick A Yates, Kwong Sum Lam, Otto Netzel, Giel G van Dooren, Alyssa Ingmundson, Kai Matuschewski, Malcolm D Mc Leod and Alexander G Maier, 11 June 2024, EMBO Molecular Medicine.
DOI: 10.1038/s44321-024-00087-1